News
AZ and Ionis' PCSK9 cholesterol drug will not move to phase ...
AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio.
